Hexavalent Influenza mRNA vaccine - Sanofi Pasteur
Latest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator Sanofi
- Class Influenza virus vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Influenza virus infections
Most Recent Events
- 06 Jan 2025 Phase-I clinical trials in Influenza virus infections (Prevention) in Australia (IM) (NCT06744205)
- 24 Dec 2024 Preclinical trials in Influenza virus infections (Prevention) in France (IM) before December 2024
- 20 Dec 2024 Sanofi Pasteur plans a phase I trial for Influenxa virus infection (Prevention) (IM, Injection) (NCT06744205)